Browsing Tag
Servier
7 posts
IDEAYA Biosciences (IDYA) stock in focus as ASCO 2026 late-breaker sets up fuller OptimUM-02 readout
IDEAYA Biosciences heads to ASCO 2026 with full OptimUM-02 data. Read why the late-breaking slot could matter for IDYA stock and melanoma strategy.
Servier bets $2.5bn on pediatric cancer specialist Day One Biopharmaceuticals (Nasdaq: DAWN)
Servier is acquiring Day One Biopharmaceuticals for $2.5B to expand its rare oncology pipeline. Discover what the deal means for pediatric cancer drug innovation.
Teva Pharmaceuticals slammed with €462.6m fine for blocking Copaxone competitors
Teva Pharmaceuticals, the generics powerhouse, has been slapped with a hefty fine of €462.6 million by the European…
Servier closes acquisition of Danish antibody discovery company Symphogen
Servier has wrapped up its previously announced acquisition of Symphogen, a Danish antibody discovery company, for an undisclosed…
Servier to acquire Danish antibody discovery company Symphogen
Servier acquisition of Symphogen : French pharma company Servier has agreed to acquire Danish antibody discovery company Symphogen,…
Pixuvri EMA approval : Servier NHL drug secures standard marketing authorization in Europe
Pixuvri EMA approval : French pharma company Servier has secured full approval for Pixuvri (pixantrone) from the European…
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration…